Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; The incidence is not reduced

Leukemia

Volumn 27, Issue 4, 2013, Pages 829-835

  Shimoni, A ^a   Shem Tov, N ^a   Chetrit, A ^b   Volchek, Y ^a   Tallis, E ^a   Avigdor, A ^a   Sadetzki, S ^b   Yerushalmi, R ^a   Nagler, A ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

Author keywords

reduced intensity conditioning; secondary malignancies; stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TREOSULFAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; BREAST ADENOCARCINOMA; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVOR; CHEMORADIOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; COLON ADENOCARCINOMA; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG MEGADOSE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HAZARD RATIO; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HODGKIN DISEASE; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; METASTASIS; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PANCREAS ADENOCARCINOMA; PHYSICIAN; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK FACTOR; SARCOMA; SKIN CANCER; SQUAMOUS CELL CARCINOMA; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84876134232     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.299     Document Type: Article

References (26)

1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363: 2091-2101.
2. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230-2239.
3. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Soce G, Travis LB et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904.
4. Kolb HJ, Socie G, Duell T, Van Lint MT, Tichelli A, Apperley JF et al. Malignant neoplasms in long-term survivors of bone marrow transplantation. Late effects working party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med 1999; 131: 738-744.
5. Bhatia S, Louie AD, Bhatia R, O'Donnell MR, Fung H, Kashyap A et al. Solid cancers after bone marrow transplantation. J Clin Oncol 2001; 19: 464-471.
6. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoietic stem cell transplantation. Cancer 2007; 109: 84-92.
7. Curtis RE, Metayer C, Rizzo JD, Socie G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802-3811.
8. Rizzo JD, Curtis RE, Socie G, Sobocinski KA, Gilbert E, Landgren O et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 1175-1183.
9. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 2011; 117: 316-322.
10. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
11. Shimoni A, Shem-Tov N, Volchek Y, Danylesko I, Yerushalmi R, Nagler A. Allogeneic stem-cell transplantation for AML and MDS with treosulfan compared with busulfan-based regimens; Reduced toxicity Vs. reduced intensity. Bone Marrow Transplant 2012; 47: 1274-1282.
12. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695-706.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos 1958; 53: 457-481.
14. Allan JM, Travis LB. Mechanism of therapy-related carcinogenesis. Nat Rev Cancer 2005; 5: 943-955.
15. Themeli M, Petrikkos L, Waterhouse M, Bertz H, Lagadinou E, Zoumbos N et al. Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia. Leukemia 2010; 24: 536-543.
16. Savani BN, Stratton P, Shenoy A, Kozanas E, Goodman S, Barrett AJ. Increased risk of cervical dysplasia in long-term survivors of allogeneic stem cell transplantation-implications for screening and HPV vaccination. Biol Blood Marrow Transplant 2008; 14: 1072-1075.
17. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002; 41: 93-103.
18. Sacchi S, Marcheselli L, Bari A, Marcheselli R, Pozzi S, Luminari S et al. Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica 2008; 93: 398-404.
19. Tam CS, Seymour JF, Prince HM, Kenealy M, Wolf M, Januszewicz EH et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006; 91: 1546-1550.
20. Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood 2011; 118: 3525-3527.
21. Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY et al. Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 2010; 11: 331-338.
22. Leisenring W, Friedman DL, Flowers ME, Schwartz JL, Deeg HJ. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol 2006; 24: 1119-1126.
23. Cavalier M, Shmalo JA, Yu M, Billings SD, Abonour R, Nelson Jr RP. Skin cancer after nonmyeloablative hematopoietic cell transplantation. Bone Marrow Transplant 2006; 37: 1103-1108.
24. Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S et al. Development of leukemia in donor cells after allogeneic stem cell transplantation-a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2005; 90: 969-975.
25. Wiseman DH. Donor cell leukemia: a review. Biol Blood Marrow Transplant 2011; 17: 771-789.
26. Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 2012; 47: 337-341.